Latest Period
Q2 2026
Security Snapshot
Dianthus Therapeutics, Inc. /DE/ - Common Stock, par value $0.001 per share (DNTH) Institutional Ownership
CUSIP: 252828108
13F Institutional Holders and Ownership History from Q3 2023 to Q2 2026
Institutions Reporting
266
Shares (Excl. Options)
65,754,452
Price
$97.48
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- DNTH on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 65,754,452
- Total 13F value
- $6,398,483,248
- Portfolio coverage rank
- 0.01%
- Share change
- +3,878,994
- Value change
- +$444,748,129
- Number of holders
- 266
- Shares outstanding
- 54,733,903
- SEC-reported price per share
- $99.91
- Insider filing price
- $99.91
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock, par value $0.001 per share is tracked under CUSIP 252828108.
- 266 institutions reported positions in Q2 2026.
- 14 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 239 to 266 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $5,141,754,510 to $6,398,483,248.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 266 institutions filings for Q2 2026.
Security key
252828108
Latest holder period
Q2 2026
13F holders
266
13D/G owners
14
CIK / CUSIP context first
Open Q2 2026 holders
DNTH full holder history
Dianthus Therapeutics, Inc. /DE/ SEC filings
Dianthus Therapeutics, Inc. /DE/ company facts
Dianthus Therapeutics, Inc. /DE/ insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 252828108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
14
Security
DNTH
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 12% | +71% | $650,429,955 | +$269,089,075 | 6,632,303 | +71% | T. Rowe Price Investment Management, Inc. | 31 Jul 2026 |
| FMR LLC | 15% | +7.1% | $234,944,605 | +$58,553,941 | 5,970,638 | +33% | FMR LLC | 30 Sep 2025 |
| BlackRock, Inc. | 6.4% | +26% | $341,584,350 | +$84,822,957 | 3,504,166 | +33% | BlackRock, Inc. | 30 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.9% | +22% | $316,754,528 | +$62,186,089 | 3,229,882 | +24% | Wellington Management Group LLP | 30 Jun 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 4.8% | -20% | $239,391,447 | 2,611,733 | 0% | RA Capital Management, L.P. | 31 Mar 2026 | |
| Fairmount Funds Management LLC | 4.9% | -50% | $72,191,285 | -$64,524,950 | 2,139,635 | -47% | Fairmount Funds Management LLC | 21 Nov 2025 |
| Avidity Partners Management LP | 4.9% | -50% | $70,995,168 | -$43,010,234 | 2,104,184 | -38% | Avidity Partners Management LP | 17 Nov 2025 |
| Octagon Capital Advisors LP | 3.6% | -42% | $178,431,497 | -$43,080,200 | 1,946,667 | -19% | Octagon Capital Advisors LP | 31 Mar 2026 |
| Sirenia Capital Management LP | 3.1% | -44% | $166,400,371 | -$108,011,454 | 1,696,751 | -39% | Sirenia Capital Management LP | 30 Jun 2026 |
| TCG Crossover GP II, LLC | 4.7% | $32,660,322 | 1,501,624 | TCG Crossover GP II, LLC | 31 Mar 2025 | |||
| BCLS Fund III Investments, LP | 3.1% | -55% | $51,780,350 | -$45,896,187 | 1,315,892 | -47% | BCLS Fund III Investments, LP | 30 Sep 2025 |
| Vestal Point Capital, LP | 3% | -70% | $46,433,000 | -$79,487,000 | 1,180,000 | -63% | Vestal Point Capital, LP | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 3.1% | $20,060,000 | 1,000,000 | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2025 | |||
| Point72 Asset Management, L.P. | 1.2% | -81% | $58,992,284 | -$214,307,954 | 643,599 | -78% | Point72 Asset Management, L.P. | 31 Mar 2026 |
As of 30 Jun 2026, 266 institutional investors reported holding 65,754,452 shares of Dianthus Therapeutics, Inc. /DE/ - Common Stock, par value $0.001 per share (DNTH). This represents 120% of the company’s total 54,733,903 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
89%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 8,199,893 | +5.6% | 0.03% | $799,325,570 |
| BlackRock, Inc. | 7.5% | 4,123,822 | +30% | 0.01% | $401,990,169 |
| T. Rowe Price Investment Management, Inc. | 7.1% | 3,888,456 | +201% | 0.25% | $379,047,000 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.9% | 3,229,882 | +24% | 0.05% | $314,848,897 |
| Fairmount Funds Management LLC | 4.6% | 2,537,191 | 0% | 16% | $247,325,379 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.6% | 2,514,946 | +119% | 0.02% | $245,158,000 |
| STATE STREET CORP | 4.3% | 2,357,440 | +69% | 0.01% | $229,798,634 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 2,159,568 | +6.3% | 0% | $210,514,689 |
| Avidity Partners Management LP | 3.8% | 2,104,184 | 0% | 33% | $205,115,856 |
| Octagon Capital Advisors LP | 3.4% | 1,841,667 | -5.4% | 16% | $179,525,699 |
| TCG Crossover Management, LLC | 3.1% | 1,676,624 | 0% | 3.9% | $163,437,308 |
| FRED ALGER MANAGEMENT, LLC | 2.4% | 1,302,493 | +12% | 0.42% | $126,967,018 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 1,258,502 | +37% | 0.01% | $122,696,604 |
| Venrock Adviser, LLC | 2.2% | 1,180,000 | 0% | 3.5% | $115,026,400 |
| UBS Group AG | 2.1% | 1,140,260 | +46% | 0.02% | $111,152,545 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2.1% | 1,125,313 | +10% | 1.1% | $109,695,511 |
| JENNISON ASSOCIATES LLC | 1.9% | 1,021,763 | +111% | 0.06% | $99,601,453 |
| Polar Capital Holdings Plc | 1.9% | 1,018,726 | -5.3% | 0.28% | $99,305,410 |
| CITADEL ADVISORS LLC | 1.8% | 974,911 | -39% | 0.05% | $95,034,324 |
| FRANKLIN RESOURCES INC | 1.8% | 968,983 | +0.08% | 0.02% | $94,456,440 |
| BAKER BROS. ADVISORS LP | 1.6% | 852,164 | 0% | 0.42% | $83,068,947 |
| ALLIANCEBERNSTEIN L.P. | 1.5% | 834,150 | 0% | 0.03% | $70,001,868 |
| Logos Global Management LP | 1.5% | 800,000 | +100% | 3.4% | $77,984,000 |
| Cormorant Asset Management, LP | 1.4% | 750,000 | -21% | 3.8% | $73,110,000 |
| BRAIDWELL LP | 1.1% | 594,562 | -34% | 2.1% | $57,957,904 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
12
Latest
Q2 2026
Rows shown
1-12 of 12
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 65,754,452 | $6,398,483,248 | +$444,748,129 | $97.48 | 266 |
| 2026 Q1 | 61,271,372 | $5,141,754,510 | +$1,107,843,049 | $83.92 | 239 |
| 2025 Q4 | 49,121,649 | $2,024,311,315 | +$67,678,158 | $41.21 | 167 |
| 2025 Q3 | 46,828,772 | $1,842,663,442 | +$358,133,968 | $39.35 | 140 |
| 2025 Q2 | 39,106,709 | $728,558,630 | +$24,440,177 | $18.63 | 101 |
| 2025 Q1 | 37,715,319 | $685,461,303 | +$43,246,773 | $18.14 | 97 |
| 2024 Q4 | 35,126,689 | $765,706,199 | +$63,092,353 | $21.80 | 94 |
| 2024 Q3 | 31,364,805 | $858,714,506 | +$44,837,092 | $27.38 | 90 |
| 2024 Q2 | 29,702,499 | $768,778,734 | +$87,583,327 | $25.88 | 74 |
| 2024 Q1 | 26,075,021 | $782,250,559 | +$479,966,613 | $30.00 | 75 |
| 2023 Q4 | 10,291,119 | $106,507,945 | +$518,588 | $10.40 | 38 |
| 2023 Q3 | 10,072,640 | $136,328,208 | +$136,328,208 | $13.67 | 30 |